Speaker 1: Bloomberg Audio Studios podcasts, radio news, The Stock Movers podcast,
Speaker 1: your roundup of companies making moves in the stock market,
Speaker 1: harnessing the power of Bloomberg data.
Speaker 2: Let's look at some stocks on the move today. We
Speaker 2: are joined by Bloomberg's Critty Gupta on a choppy pre
Speaker 2: market session for stocks as a whole creaty. That is
Speaker 2: certainly what we are seeing at the micro level. For Delta,
Speaker 2: they just reported earnings. What's the stock doing?
Speaker 3: Good morning, Good morning, Nathan. We are getting the very
Speaker 3: first inclination of companies starting to suspend their guidance. This
Speaker 3: is a really big deal. I'm having a little bit
Speaker 3: of COVID deja vous here because when you look at
Speaker 3: some of these numbers, the earnings revisions are key to
Speaker 3: that chart. You've seen massive numbers, massive hits to the
Speaker 3: tech valuations. A lot of that is only if you
Speaker 3: do indeed get those earnings revisions from these companies, or
Speaker 3: like in COVID, you do get a suspension of the
Speaker 3: guid of guidance there as well. So Delta DAL is
Speaker 3: your ticker this morning, actually coming out of the gates
Speaker 3: hire by about three percent. The market is buying this,
Speaker 3: which is non traditional giving that they're withdrawing they're full
Speaker 3: your guidance, calling it given current uncertainty. They're saying that
Speaker 3: growth has largely stalled. But when you look at their
Speaker 3: first quarter numbers, they are actually coming in line with expectation.
Speaker 3: So the markets buying even just that is quite something
Speaker 3: to witness because again, a very non traditional reaction for
Speaker 3: really any company that would be suspending it's guidance. Let's
Speaker 3: talk about some of the other weights in this market.
Speaker 3: I think the story of the morning. Your pharma stocks
Speaker 3: are taking the biggest beating this morning. I'm just going
Speaker 3: to run through the laundry list of names this morning, Nathan,
Speaker 3: if i can. Abby is top of that list.
Speaker 1: ABBV is your.
Speaker 3: Ticker down just shy of four percent this morning, one
Speaker 3: hundred and sixty nine dollars to share, Abbot right on
Speaker 3: its heels. ABT down about the same margin, trading at
Speaker 3: one hundred and nineteen dollars a share.
Speaker 1: There.
Speaker 3: Then you've got Giliad Sciences as well, GILD down about
Speaker 3: three percent. I'm seeing that their bonds are selling off
Speaker 3: in a very big way this morning. Really keep an
Speaker 3: eye on a on a stock simply because or some
Speaker 3: of the kind of bonds that are trading. Credit seems
Speaker 3: to be leading this equity market, So anything that has
Speaker 3: a massive corporate bond hit is going to be magnified
Speaker 3: in the equity market. You're seeing that with gilliad Sciences,
Speaker 3: like I said, Gild down about three percent, Bristol Meyers
Speaker 3: squib as well, Bmy down about three percent, trading at
Speaker 3: fifty one dollars a share, and some of our favorites
Speaker 3: there Pfizer PFE down a whopping three percent, trading at
Speaker 3: twenty one dollars share. Nathan, I could go on and on.
Speaker 3: The message this morning is if you are a pharmaceutical hit,
Speaker 3: you are taking a massive hit when it comes to
Speaker 3: your stock. And a lot of those lead actually by
Speaker 3: some of the pain you've seen right here in Europe
Speaker 3: as well. The likes of Nova Nordisks, for example, have
Speaker 3: really been selling off this morning in Europe, alongside Roche
Speaker 3: and Santa Fee as well. Nova Nordisk, I should mention
Speaker 3: the ADRs also are available in the United States Envo
Speaker 3: for that ticker, trading at about sixty dollars and change
Speaker 3: down about one point two percent. I'll just mention that
Speaker 3: about sixty percent of Nova Nordisk's revenue comes from the
Speaker 3: United States, so this is a really great spot to
Speaker 3: look at when you're talking about some of the movement
Speaker 3: there in the pharmaceutical space. We're also getting some numbers
Speaker 3: coming out of Walmart, several comments coming from the CEO
Speaker 3: and the last twenty four hours thing that they're being
Speaker 3: focused on keeping price as low, prices as low as
Speaker 3: they possibly can, and really looking at some cost cutting measures.
Speaker 3: They're reaffirming their first quarter sales guidance. In their full
Speaker 3: year twenty twenty six guidance remains unchanged, so that's going
Speaker 3: to be again another major one to watch, Nathan. For me,
Speaker 3: Walmart's WMT is the tell those shares hire by two
Speaker 3: percent this morning.
Speaker 1: The Stock Movers podcast from Bloomberg Radio. Check back with
Speaker 1: us throughout today for the latest roundup of companies making
Speaker 1: news on Wall Street and for the latest market moving headlines.
Speaker 1: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
Speaker 1: dot com, and on Applecarplay and Android Auto with the
Speaker 1: Bloomberg Business app.